Publication:


abstract

Migraine headaches are debilitatingly painful and poorly managed. facial allodynia is often associated with migraine, and clinical evidence indicates that it is a critical point in migraine progression. That is, if the migraine can be treated prior to the onset of facial allodynia, the migraine can be halted using triptans, whereas if treatment is administered after facial allodynia has begun, the treatment is ineffective. The meninges and the immune cells therein have been implicated in migraine facial pain. Indeed, application of inflammatory mediators over the meninges has been used to study changes in pain responsive neurons in trigeminal complex, and changes in their receptive fields. Much of this research has been carried out in anesthetized rats, which limits the clinical application. Our Indwelling supradural catheter model, in which inflammatory mediators can be administered to the meninges in awake and freely moving rats, allows for the assessment of behavioral changes shortly after injection. Following administration of inflammatory soup (histamine, serotonin, bradykinin, and prostaglandin E2) or the immunogenic HIV-1 coat protein gp120 results in reliable periorbital mechanical allodynia. This model provides an additional means to study the neurocircuitry and neuropharmacology of facial allodynia. Here, we describe detailed methods for the placement of the catheter, injection procedures, and assessment of facial allodynia.

Related Articles
A novel method for modeling facial allodynia associated with migraine in awake and freely moving rats.
J Neurosci Methods. 2010
A novel method for modeling facial allodynia associated with migraine in awake and freely moving rats.
Wieseler J, Ellis A, Sprunger D, Brown K, McFadden A, Mahoney J, Rezvani N, Maier SF, Watkins LR. J Neurosci Methods. 2010 Jan 15; 185(2):236-45. Epub 2009 Oct 29.
Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors.
Headache. 2005
Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors.
Jakubowski M, Levy D, Goor-Aryeh I, Collins B, Bajwa Z, Burstein R. Headache. 2005 Jul-Aug; 45(7):850-61.
Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons.
J Neurophysiol. 1998
Chemical stimulation of the intracranial dura induces enhanced responses to facial stimulation in brain stem trigeminal neurons.
Burstein R, Yamamura H, Malick A, Strassman AM. J Neurophysiol. 1998 Feb; 79(2):964-82.
Review Central sensitisation and cutaneous allodynia in migraine: implications for treatment.
CNS Drugs. 2004
Review Central sensitisation and cutaneous allodynia in migraine: implications for treatment.
Landy S, Rice K, Lobo B. CNS Drugs. 2004; 18(6):337-42.
Review Effects of sensitization of trigeminovascular neurons to triptan therapy during migraine.
Rev Neurol (Paris). 2005
Review Effects of sensitization of trigeminovascular neurons to triptan therapy during migraine.
Burstein R, Levy D, Jakubowski M. Rev Neurol (Paris). 2005 Jul; 161(6-7):658-60.